Physician profile
Mark A Rodgers
NPI 1811954936
$8,404.61
in general payments reported to CMS, 2019-2025
47 companies · $20.84 in 2025
The $20.84 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,717 · 2020: $1,676 · 2021: $3,911 · 2022: $1,015 · 2023: $41.52 · 2024: $24.00 · 2025: $20.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $86.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $86.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,473.74 | 2020-2021 | |
| Abbvie INC. | $786.91 | 2019-2022 | |
| Novo Nordisk INC | $630.38 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $611.80 | 2019-2022 | |
| Glaxosmithkline, LLC. | $513.83 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $356.99 | 2019-2022 | |
| Lilly USA, LLC | $293.03 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $275.95 | 2019-2022 | |
| Pfizer INC. | $266.29 | 2019-2020 | |
| Amgen INC. | $255.54 | 2019-2022 | |
| Allergan, INC. | $254.49 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $208.96 | 2019-2022 | |
| Daiichi Sankyo INC. | $199.06 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $197.12 | 2019-2022 | |
| Abbott Laboratories | $188.63 | 2020-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Rodgers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.